$132.81
Value $328B
MRK and PCRX stock compared: price, dividend, valuation and results, from SEC filings.
$132.81
Value $328B
$36.48
Value $1.5B
Merck & Company (MRK) has a market value of $328B and Pacira BioSciences (PCRX) $1.5B. The P/E is 133.9 for MRK and 39.2 for PCRX. Dividend yield: MRK 2.56%, PCRX none.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
MRK$328B
PCRX$1.5B
MRK is 222 times PCRX
Revenue, 12 months
MRK$67.4B
PCRX$743M
MRK is 91 times PCRX
Net income, 12 months
MRK$2.5B
PCRX$38M
MRK is 65 times PCRX
Operating margin
MRK–
PCRX4.8%
ROIC
MRK3.9%
PCRX2.4%
1.5 points apart
P/E
MRK133.9
PCRX39.2
MRK is 3.4 times PCRX
Dividend yield
MRK2.6%
PCRX0.0%
2.6 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
Prices are not available right now.
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
MRKMerck & CompanyPCRXPacira BioSciences
| Price | $132.81 | $36.48 |
|---|---|---|
| Market value | $328B | $1.5B |
| Enterprise value (EV) | $372B | $1.5B |
| P/E | 133.9 | 39.2 |
| P/E, 5-year median | 14.8 | – |
| P/B | 7.3 | 2.1 |
| EV/EBIT | 78.2 | 41.2 |
| Free cash flow yield | 4.5% | 11.4% |
| Revenue, 12 months | $67.4B | $743M |
|---|---|---|
| Net income, 12 months | $2.5B | $38M |
| Free cash flow, 12 months | $14.7B | $169M |
| Earnings per share, 12 months | $0.98 | $0.93 |
| Revenue growth, year on year | 1.3% | 3.6% |
| Revenue growth a year, past | +9.4%over 5 years | +11.1%over 5 years |
| EPS growth a year, past | +21.2%over 5 years | -45.5%over 5 years |
| Gross margin | 71.8% | 78.7% |
|---|---|---|
| Operating margin | – | 4.8% |
| Net margin | 3.6% | 5.1% |
| ROIC | 3.9% | 2.4% |
| ROE | 5.2% | 5.5% |
| Cash | $9.7B | $296M |
|---|---|---|
| Total debt | $53.8B | $340M |
| Net debt / EBITDA | 5.7 | -0.0 |
| Interest cover | 2.4× | 2.5× |
| Dividend yield | 2.6% | – |
|---|---|---|
| Dividend per share, 12 months | $3.40 | – |
| Dividend growth a year, past | +5.8%over 5 years | – |
| Buyback yield | 1.6% | 10.0% |
| Shareholder yield | 4.1% | 10.0% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Merck & Company ($328B) is about 222.3 times Pacira BioSciences ($1.5B), at today's prices.
The dividend yield at today's price is 2.56% for Merck & Company and none for Pacira BioSciences. Over the last twelve months they paid $3.40 and – per share.
At today's price, the P/E is 133.9 for MRK and 39.2 for PCRX. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 3.6% for Merck & Company and 5.1% for Pacira BioSciences, and the operating margin – and 4.8%. Revenue was $67.4B and $743M.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.